1. A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers. (1st August 2017) Authors: Smith, Patrick F.; Krishnarajah, Janakan; Nunn, Philip A.; Hill, Ron J.; Karr, Dane; Tam, D.; Masjedizadeh, Mohammad; Funk, Jens O.; Gourlay, Steve G. Journal: British journal of clinical pharmacology Issue: Volume 83:Number 11(2017) Page Start: 2367 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A thorough QTc study to evaluate the effects of oral rilzabrutinib administered alone and with ritonavir in healthy subjects. Issue 6 (3rd April 2022) Authors: Ucpinar, Sibel; Darpo, Borje; Neale, Ann; Nunn, Philip; Shu, Jin; Chu, Katherine A.; Kavanagh, Marianne; Xue, Hongqi; Phiasivongsa, Pasit; Thomas, Dolca; Smith, Patrick F. Journal: Clinical and translational science Issue: Volume 15:Issue 6(2022) Page Start: 1507 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. An evaluation of a supratherapeutic dose of inclisiran on cardiac repolarization in healthy volunteers: A phase I, randomized study. Issue 11 (5th October 2022) Authors: Kallend, David; Mason, Jay; Smith, Patrick F.; Koren, Michael J.; Stoekenbroek, Robert; He, YanLing; Wijngaard, Peter Journal: Clinical and translational science Issue: Volume 15:Issue 11(2022) Page Start: 2663 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Asia‐Inclusive Clinical Research and Development Enabled by Translational Science and Quantitative Clinical Pharmacology: Toward a Culture That Challenges the Status Quo. Issue 2 (17th April 2022) Authors: Venkatakrishnan, Karthik; Gupta, Neeraj; Smith, Patrick F.; Lin, Tiffany; Lineberry, Neil; Ishida, Tatiana; Wang, Lin; Rogge, Mark Journal: Clinical pharmacology & therapeutics Issue: Volume 113:Issue 2(2023) Page Start: 298 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Assessing the Combined Public Health Impact of Pharmaceutical Interventions on Pandemic Transmission and Mortality: An Example in SARS CoV‐2. Issue 6 (20th September 2022) Authors: Kamal, Mohamed A.; Kuznik, Andreas; Qi, Luyuan; Więcek, Witold; Hussein, Mohamed; Hassan, Hazem E.; Patel, Kashyap; Obadia, Thomas; Toroghi, Masood Khaksar; Conrado, Daniela J.; Al‐Huniti, Nidal; Casciano, Roman; O'Brien, Meagan P.; Barnabas, Ruanne V.; Cohen, Myron S.; Smith, Patrick F. Journal: Clinical pharmacology & therapeutics Issue: Volume 112:Issue 6(2022) Page Start: 1224 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Blueprint for pandemic response: Focus on translational medicine, clinical pharmacology and pharmacometrics. Issue 9 (6th May 2021) Authors: Davda, Jasmine; Reynolds, Kellie; Davis, John D.; Smith, Patrick F. Journal: British journal of clinical pharmacology Issue: Volume 87:Issue 9(2021) Page Start: 3398 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Dosing will be a key success factor in repurposing antivirals for COVID‐19. Issue 9 (17th April 2020) Authors: Smith, Patrick F.; Dodds, Michael; Bentley, Darren; Yeo, Karen; Rayner, Craig Journal: British journal of clinical pharmacology Issue: Volume 87:Issue 9(2021) Page Start: 3451 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Effect of meal and antisecretory agents on the pharmacokinetics of danoprevir/ritonavir in healthy volunteers. (10th October 2013) Authors: Morcos, Peter N.; Moreira, Sebastian A.; Navarro, Mercidita T.; Bech, Núria; Quatkemeyer, Amanda; Smith, Patrick F.; Brennan, Barbara J. Journal: Journal of pharmacy and pharmacology Issue: Volume 66:Number 1(2014:Jan.) Page Start: 23 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Effect of Ritonavir‐Boosted Danoprevir, a Potent Hepatitis C Virus Protease Inhibitor, on QTc Interval in Healthy Subjects: Results from a Thorough QT Study. Issue 5 (25th March 2013) Authors: Morcos, Peter N.; Kulkarni, Rohit; Scoon, Sally; Smith, Patrick F.; Brennan, Barbara J. Journal: Drug development research Issue: Volume 74:Issue 5(2013) Page Start: 306 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Effect of Ritonavir‐Boosted Danoprevir, a Potent Hepatitis C Virus Protease Inhibitor, on the Pharmacokinetics of Methadone in Healthy Subjects Undergoing Methadone Maintenance Therapy. Issue 3 (14th August 2013) Authors: Moreira, Sebastian A.; Morcos, Peter N.; Navarro, Mercidita T.; Bech, Nuria; Smith, Patrick F.; Brennan, Barbara J. Journal: Pharmacotherapy Issue: Volume 34:Issue 3(2014) Page Start: 220 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗